Company / Operating Cash Flow per Share
Apogee Therapeutics, Inc. Operating Cash Flow per Share History
FY2022-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$3.10
FY2024
5-year range
-$6.67 / -$2.99
FY2022-FY2024
Trend
-3.7%
vs FY2023
Sector context
#170 of 212
Health Care
What the data says
Apogee Therapeutics, Inc.'s operating cash flow per share of $-3.10 is lower than 80% of companies in the Health Care sector (FY2024). Improved from $-6.67 to $-3.10 over the past 2 years.
Based on SEC 10-K filings.
-3.10 in FY2024.
Improved from $-6.67 to $-3.10 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 20% in Health CareTop 80% of 212This company -$3.10 Sector average -$14.72
▼
+78.9% above sector average
Key checks
Key Insights
- In FY2024, operating cash flow per share decreased 3.7% year-over-year.
- Ranks #170 out of 212 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$3.10 | -3.7% |
| FY2023 | -$2.99 | +55.2% |
| FY2022 | -$6.67 | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026